Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors
Urate transporter 1 (URAT1) is a clinically validated target for the treatment of hyperuricemia and gout. Due to the absence of protein structures, the molecular design of new URAT1 inhibitors generally resorts to ligand-based approaches. Two series of biphenyl carboxylic acids were designed based o...
Main Authors: | Xianxin Hou, Yongcheng Wang, Yajun Yang, Zhiyan Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/28/21/7415 |
Similar Items
-
Two cases of acute urate nephropathy in women with asymptomatic hyperuricemia
by: L. N. Yeliseyeva, et al.
Published: (2021-03-01) -
Solving the mysteries of urate transport: structural insights into GLUT9 and URAT1
by: Mei Wang, et al.
Published: (2024-09-01) -
Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis
by: M S Eliseyev, et al.
Published: (2012-03-01) -
Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials
by: Toshinari Takahashi, et al.
Published: (2021-11-01) -
Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan
by: Masafumi Kurajoh, et al.
Published: (2024-01-01)